Weekly insulin injections promise fewer needles, but they aren't a universal solution. Experts weigh the benefits, drawbacks, and patient‑specific factors that determine the right regimen.

Key Takeaways

  • Weekly insulin reduces injection frequency while maintaining comparable glucose control.
  • Daily insulin remains advantageous for patients needing frequent dose adjustments.
  • Age, kidney function, hypoglycemia risk, and lifestyle dictate the optimal insulin schedule.

Denmark‑based pharmaceutical giant Novo Nordisk has introduced its weekly basal insulin, Awiqli (icodec), to the Indian market, marking a potential shift in diabetes management. By cutting the number of injections from 365 a year to just 52, the drug aims to simplify treatment and improve patient adherence.

Clinical Evidence Behind Weekly Insulin

The company’s ONWARDS programme, comprising six global Phase 3a trials with over 4,000 adults living with type 1 or type 2 diabetes, showed that once‑weekly insulin achieved HbA1c reductions comparable to, and in some studies slightly superior to, once‑daily basal insulin. Safety profiles remained similar, indicating that convenience does not come at the cost of glucose control.

Why Daily Dosing Still Matters

Daily basal insulins, such as glargine or degludec, allow clinicians to fine‑tune doses based on real‑time glucose readings, meals, activity levels, or illness. “Patients who need rapid dose adjustments may still benefit more from a daily regimen,” says Dr. Vijay Negalur, Head of Diabetology at KIMS Hospitals, Thane.

Impact on Patient Lifestyle and Adherence

For many with type 2 diabetes, the fear of daily injections delays insulin initiation. Dr. Rajiv Kovil of Zandra Healthcare notes, “Simplifying the injection schedule improves acceptance, adherence, and persistence—three pillars as crucial as the drug itself.” Travelers, forgetful individuals, or those burdened by complex routines may find a weekly shot dramatically improves quality of life.

Factors Clinicians Must Evaluate

Doctors should assess age, renal function, hypoglycemia risk, concomitant medications, and overall disease stability before recommending a weekly regimen. “A weekly formulation does not replace the need for regular exercise, balanced nutrition, weight management, and glucose monitoring,” adds Dr. Negalur.

Ultimately, the consensus among specialists is clear: “There is no one‑size‑fits‑all answer. The optimal insulin schedule emerges from a detailed dialogue between patient and physician, accounting for glycemic patterns, lifestyle, and long‑term goals.”